Stay updated with breaking news from Nasdaq Brns. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Barinthus Biotherapeutics (NASDAQ:BRNS – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research note issued to investors on Friday, Benzinga reports. They presently have a $8.00 price target on the stock. HC Wainwright’s price target would indicate a potential upside of 218.73% from the stock’s previous […]
Barinthus Biotherapeutics (NASDAQ:BRNS – Free Report) had its price objective cut by HC Wainwright from $15.00 to $8.00 in a research report released on Thursday, Benzinga reports. They currently have a buy rating on the stock. Separately, William Blair reaffirmed an outperform rating on shares of Barinthus Biotherapeutics in a research report on Monday, January […]
Barinthus Biotherapeutics plc (NASDAQ:BRNS – Get Free Report) was the recipient of a significant drop in short interest during the month of February. As of February 15th, there was short interest totalling 14,100 shares, a drop of 55.8% from the January 31st total of 31,900 shares. Based on an average trading volume of 12,000 shares, […]
Barinthus Biotherapeutics (NASDAQ:BRNS – Get Free Report) is one of 988 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare Barinthus Biotherapeutics to related businesses based on the strength of its valuation, risk, analyst recommendations, profitability, dividends, earnings and institutional ownership. Risk and Volatility Barinthus Biotherapeutics […]
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones...